Abstract
Overwhelming evidence supports a central role for the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimers disease (AD), and the proteases that produce Aβ from its precursor protein APP are top targets for therapeutic intervention. Considerable effort has focused on targeting γ-secretase, which generates the C-terminus of Aβ; however, γ- secretase inhibitors cause serious toxicities due to interference with the Notch signaling pathway. We have been working toward compounds that directly alter γ-secretase activity to reduce Aβ production without affecting the proteolysis of Notch. Using purified enzyme and substrate, we have shown that γ-secretase can be selectively inhibited in this way by naphthyl-substituted γ-aminoketones and γ-aminoalcohols. These early hits, however, suffered from chemical instability and/or poor potency. Iterative design, synthesis and evaluation have led to the discovery of Notch-sparing γ-secretase inhibitors with substantially increased potencies in biochemical and cellular assays. These compounds are of low molecular weight and are under evaluation for drug-like properties. The discovery and development of these compounds will be discussed.
Keywords: Protease, amyloid, inhibitors, drug discovery
Current Alzheimer Research
Title: Discovery of Notch-Sparing γ-Secretase Inhibitors
Volume: 7 Issue: 3
Author(s): C.E. Augelli-Szafran, H.-X. Wei, D. Lu, J. Zhang, Y. Gu, T. Yang, P. Osenkowski, W. Ye and M.S. Wolfe
Affiliation:
Keywords: Protease, amyloid, inhibitors, drug discovery
Abstract: Overwhelming evidence supports a central role for the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimers disease (AD), and the proteases that produce Aβ from its precursor protein APP are top targets for therapeutic intervention. Considerable effort has focused on targeting γ-secretase, which generates the C-terminus of Aβ; however, γ- secretase inhibitors cause serious toxicities due to interference with the Notch signaling pathway. We have been working toward compounds that directly alter γ-secretase activity to reduce Aβ production without affecting the proteolysis of Notch. Using purified enzyme and substrate, we have shown that γ-secretase can be selectively inhibited in this way by naphthyl-substituted γ-aminoketones and γ-aminoalcohols. These early hits, however, suffered from chemical instability and/or poor potency. Iterative design, synthesis and evaluation have led to the discovery of Notch-sparing γ-secretase inhibitors with substantially increased potencies in biochemical and cellular assays. These compounds are of low molecular weight and are under evaluation for drug-like properties. The discovery and development of these compounds will be discussed.
Export Options
About this article
Cite this article as:
Augelli-Szafran C.E., Wei H.-X., Lu D., Zhang J., Gu Y., Yang T., Osenkowski P., Ye W. and Wolfe M.S., Discovery of Notch-Sparing γ-Secretase Inhibitors, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050920
DOI https://dx.doi.org/10.2174/156720510791050920 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Purification and Characterization of Human Brain Serine Racemase Expressed in Moderately Halophilic Bacteria
Protein & Peptide Letters Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine Can Selective Ligands for Glutamate Binding Proteins be Rationally Designed?
Current Topics in Medicinal Chemistry A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry An Optimal Approach for Selecting Discriminant Regions for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
Current Pharmaceutical Design A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Synthetic Androgen and New Psycho-Active Compounds (Smart Drugs) Abuse and Dependance. Neuropathological and Toxicological Findings, with an Approach Designed For the Future)
Current Neuropharmacology Determination of Lipoic Acid in the form of 2-S-pyridinium Derivative by High-performance Liquid Chromatography with Ultraviolet Detection
Current Analytical Chemistry EDITORIAL: Impact of Biological Science to Medicinal Chemistry
Current Topics in Medicinal Chemistry Allosteric Modulation of the Calcium-Sensing Receptor
Current Neuropharmacology Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry LC-MS/MS Determination of Bromperidol in Biological Matrices: Method Validation and Forensic Application
Current Pharmaceutical Analysis Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Foods for Health and to Treat Diseases
Current Pediatric Reviews Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology